Tenosynovitis Induced by an Immune Checkpoint Inhibitor: A Case Report and Literature Review

A 51-year-old man underwent second-line treatment for non-small-cell lung cancer (NSCLC) with the immune checkpoint inhibitor (ICI) pembrolizumab. On day 2 after two cycles of pembrolizumab, he presented with edema limited to the left third, fourth, and fifth fingers. Based on symptoms, laboratory r...

Descripción completa

Detalles Bibliográficos
Autores principales: Murakami, Shoko, Nagano, Tatsuya, Nakata, Kyosuke, Onishi, Akira, Umezawa, Kanoko, Katsurada, Naoko, Yamamoto, Masatsugu, Tachihara, Motoko, Kobayashi, Kazuyuki, Nishimura, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815895/
https://www.ncbi.nlm.nih.gov/pubmed/31243239
http://dx.doi.org/10.2169/internalmedicine.2556-19
Descripción
Sumario:A 51-year-old man underwent second-line treatment for non-small-cell lung cancer (NSCLC) with the immune checkpoint inhibitor (ICI) pembrolizumab. On day 2 after two cycles of pembrolizumab, he presented with edema limited to the left third, fourth, and fifth fingers. Based on symptoms, laboratory results, and contrast-enhanced magnetic resonance imaging (MRI) findings, we diagnosed him with tenosynovitis. We prescribed oral prednisolone (0.5 mg/kg/day), and pembrolizumab was continued. Prednisolone immediately relieved the symptoms, and the tumor was still shrinking on day 21 after eight cycles of pembrolizumab. ICI-induced tenosynovitis was managed while continuing ICI usage, suggesting that 0.5 mg/kg/day prednisone might be effective for tenosynovitis without ICI cessation.

Ejemplares similares